CompletedNot Applicable

A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma

Australia29 participantsStarted 2013-04

Plain-language summary

To treat patients with scleroderma by blocking the expression of LOXL2. The investigators first need to confirm (through observation) that LOXL2 is overexpressed in disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Over 18 years of age * Documented diagnosis of scleroderma * Willing and able to provide written informed consent Exclusion Criteria: * Use of experimental therapies within 28 days prior to Screening. * Aspirin use \> 81 mg daily within 1 week prior to Screening. * Any lab abnormality or concurrent medical condition that, in the opinion of the investigator would make the patient ineligible for the study

What they're measuring

Summarized the number and percentage of subjects with elevated LOXL2 levels

Timeframe: Baseline

Trial details

NCT IDNCT01881529

SponsorGilead Sciences

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2014-03

View on ClinicalTrials.gov More Limited Scleroderma trials